We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Abbott (ABT) Stock Moves -2%: What You Should Know
Read MoreHide Full Article
The latest trading session saw Abbott (ABT - Free Report) ending at $124.50, denoting a -2% adjustment from its last day's close. The stock's change was more than the S&P 500's daily loss of 3.46%. Meanwhile, the Dow lost 2.5%, and the Nasdaq, a tech-heavy index, lost 4.31%.
Shares of the maker of infant formula, medical devices and drugs witnessed a loss of 2.49% over the previous month, beating the performance of the Medical sector with its loss of 10.85% and the S&P 500's loss of 5.27%.
Analysts and investors alike will be keeping a close eye on the performance of Abbott in its upcoming earnings disclosure. The company's earnings report is set to go public on April 16, 2025. On that day, Abbott is projected to report earnings of $1.07 per share, which would represent year-over-year growth of 9.18%. Meanwhile, the latest consensus estimate predicts the revenue to be $10.42 billion, indicating a 4.54% increase compared to the same quarter of the previous year.
Looking at the full year, the Zacks Consensus Estimates suggest analysts are expecting earnings of $5.15 per share and revenue of $44.42 billion. These totals would mark changes of +10.28% and +5.9%, respectively, from last year.
It is also important to note the recent changes to analyst estimates for Abbott. These recent revisions tend to reflect the evolving nature of short-term business trends. As such, positive estimate revisions reflect analyst optimism about the company's business and profitability.
Empirical research indicates that these revisions in estimates have a direct correlation with impending stock price performance. To benefit from this, we have developed the Zacks Rank, a proprietary model which takes these estimate changes into account and provides an actionable rating system.
The Zacks Rank system, which ranges from #1 (Strong Buy) to #5 (Strong Sell), has an impressive outside-audited track record of outperformance, with #1 stocks generating an average annual return of +25% since 1988. Within the past 30 days, our consensus EPS projection has moved 0.04% higher. Abbott currently has a Zacks Rank of #2 (Buy).
Investors should also note Abbott's current valuation metrics, including its Forward P/E ratio of 24.08. Its industry sports an average Forward P/E of 14.83, so one might conclude that Abbott is trading at a premium comparatively.
We can also see that ABT currently has a PEG ratio of 2.31. The PEG ratio is similar to the widely-used P/E ratio, but this metric also takes the company's expected earnings growth rate into account. ABT's industry had an average PEG ratio of 1.94 as of yesterday's close.
The Medical - Products industry is part of the Medical sector. Currently, this industry holds a Zacks Industry Rank of 180, positioning it in the bottom 28% of all 250+ industries.
The Zacks Industry Rank is ordered from best to worst in terms of the average Zacks Rank of the individual companies within each of these sectors. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Ensure to harness Zacks.com to stay updated with all these stock-shifting metrics, among others, in the next trading sessions.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Abbott (ABT) Stock Moves -2%: What You Should Know
The latest trading session saw Abbott (ABT - Free Report) ending at $124.50, denoting a -2% adjustment from its last day's close. The stock's change was more than the S&P 500's daily loss of 3.46%. Meanwhile, the Dow lost 2.5%, and the Nasdaq, a tech-heavy index, lost 4.31%.
Shares of the maker of infant formula, medical devices and drugs witnessed a loss of 2.49% over the previous month, beating the performance of the Medical sector with its loss of 10.85% and the S&P 500's loss of 5.27%.
Analysts and investors alike will be keeping a close eye on the performance of Abbott in its upcoming earnings disclosure. The company's earnings report is set to go public on April 16, 2025. On that day, Abbott is projected to report earnings of $1.07 per share, which would represent year-over-year growth of 9.18%. Meanwhile, the latest consensus estimate predicts the revenue to be $10.42 billion, indicating a 4.54% increase compared to the same quarter of the previous year.
Looking at the full year, the Zacks Consensus Estimates suggest analysts are expecting earnings of $5.15 per share and revenue of $44.42 billion. These totals would mark changes of +10.28% and +5.9%, respectively, from last year.
It is also important to note the recent changes to analyst estimates for Abbott. These recent revisions tend to reflect the evolving nature of short-term business trends. As such, positive estimate revisions reflect analyst optimism about the company's business and profitability.
Empirical research indicates that these revisions in estimates have a direct correlation with impending stock price performance. To benefit from this, we have developed the Zacks Rank, a proprietary model which takes these estimate changes into account and provides an actionable rating system.
The Zacks Rank system, which ranges from #1 (Strong Buy) to #5 (Strong Sell), has an impressive outside-audited track record of outperformance, with #1 stocks generating an average annual return of +25% since 1988. Within the past 30 days, our consensus EPS projection has moved 0.04% higher. Abbott currently has a Zacks Rank of #2 (Buy).
Investors should also note Abbott's current valuation metrics, including its Forward P/E ratio of 24.08. Its industry sports an average Forward P/E of 14.83, so one might conclude that Abbott is trading at a premium comparatively.
We can also see that ABT currently has a PEG ratio of 2.31. The PEG ratio is similar to the widely-used P/E ratio, but this metric also takes the company's expected earnings growth rate into account. ABT's industry had an average PEG ratio of 1.94 as of yesterday's close.
The Medical - Products industry is part of the Medical sector. Currently, this industry holds a Zacks Industry Rank of 180, positioning it in the bottom 28% of all 250+ industries.
The Zacks Industry Rank is ordered from best to worst in terms of the average Zacks Rank of the individual companies within each of these sectors. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Ensure to harness Zacks.com to stay updated with all these stock-shifting metrics, among others, in the next trading sessions.